Investigation of canine parvovirus occurrence in cats with clinical signs of feline panleukopenia in Slovakia – pilot study

Group	Sample ID	Breed	Sex	Age	FPV vaccination	Anamnesis
I. clinical signs (n = 21)	1	crossbreed	female	3 months	no	vomiting, diarrhoea
	2	crossbreed	male	3 months	no	vomiting, diarrhoea, lethargy
	3	crossbreed	female	2 months	no	vomiting, diarrhoea, fever
	4	ESH	female	6 months	no	lethargy, anorexia, fever
	5	ESH	female	5 months	no	lethargy, anorexia
	6	crossbreed	female	2 months	no	vomiting, diarrhoea
	7	crossbreed	male	3 months	no	vomiting, lethargy
	8	crossbreed	female	3 months	no	lethargy, fever
	9	crossbreed	female	3 months	no	vomiting, diarrhoea, fever
	10	ESH	female	3 years	no	lethargy, fever
	11	crossbreed	female	4 months	yes	vomiting, lethargy, fever
	12	ESH	female	3 years	no	vomiting, lethargy, anorexia
	13	crossbreed	male	7 months	no	vomiting, lethargy, fever
	14	crossbreed	male	6 months	no	diarrhoea, fever, vomiting
	15	crossbreed	male	5 years	yes	diarrhoea
	16	ESH	male	3 months	no	vomiting, lethargy, fever
	17	ESH	male	5 months	no	vomiting, lethargy, fever, diarrhoea
	18	crossbreed	male	5 months	no	vomiting, lethargy, fever
	19	ESH	male	6 months	no	vomiting, lethargy, fever
	20	crossbreed	male	1 year	no	vomiting, diarrhoea
	21	crossbreed	male	3 months	no	diarrhoea, vomiting
II. close contact with parvovirus-infected animal (n = 29)	1	crossbreed	female	4 years	yes	healthy
	2	crossbreed	female	6 months	no	healthy
	3	crossbreed	male	4 months	no	healthy
	4	crossbreed	female	4 years	yes	healthy
	5	crossbreed	female	5 years	yes	healthy
	6	ESH	female	2 years	no	healthy
	7	ESH	female	1 year	no	healthy
	8	ESH	female	4 years	yes	healthy
	9	crossbreed	male	5 years	yes	healthy
	10	ESH	female	4 months	no	diarrhoea
	11	crossbreed	female	3 months	no	diarrhoea
	12	crossbreed	male	2 months	no	diarrhoea
	13	crossbreed	female	3 months	no	diarrhoea, vomiting
	14	crossbreed	male	3 months	no	healthy
	15	ESH	female	1 year	no	healthy
	16	crossbreed	male	5 months	no	healthy
	17	crossbreed	male	2 years	yes	healthy
	18	crossbreed	male	2 years	yes	intermittent diarrhoea
	19	crossbreed	female	5 months	no	diarrhoea, overcame FPL
	20	ESH	female	5 years	no	healthy
	21	crossbreed	male	2 years	yes	intermittent diarrhoea
	22	crossbreed	female	4 months	no	healthy
	23	ESH	female	2 years	no	healthy
	24	crossbreed	female	1 year	no	healthy, overcame FPL
	25	crossbreed	male	1 year	yes	healthy
	26	crossbreed	female	5 months	no	diarrhoea, overcame FPL
	27	crossbreed	male	4 months	no	vomiting
	28	crossbreed	female	3 years	yes	healthy
	29	crossbreed	female	6 months	no	healthy, overcame FPL
III. clinically healthy (n = 9)	1	ESH	male	1 year	yes	healthy
	2	ESH	female	2 years	yes	healthy
	3	crossbreed	male	7 months	yes	healthy
	4	crossbreed	female	3 years	yes	healthy
	5	crossbreed	male	3 months	yes	healthy
	6	crossbreed	male	5 months	yes	healthy
	7	crossbreed	female	1 year	yes	healthy
	8	crossbreed	female	2 years	yes	healthy
	9	ESH	male	1 year	yes	healthy

1 ESH – European shorthair; FPL – feline panleukopenia

Table 2.

Antigen-based detection of parvovirus infection in rectal swab samples of European shorthair and crossbred cats in central Slovakia grouped by feline panleukopenia status

Group	Sample ID	CPV antigen test
I. clinical signs (n = 21)	1–21	+
II. close contact with parvovirus-infected animal (n = 29)	1–9; 11–26; 28, 29	-
II. close contact with parvovirus-infected animal (n = 29)	10, 27	+
III. clinically healthy (n = 9)	1–9	-

1 CPV – canine parvovirus; + – positive result; - – negative result

Table 3.

Summary of parvovirus infection findings in rectal swab samples of European shorthair and crossbred cats in central Slovakia grouped by feline panleukopenia status

Groups	CPV antigen test		PCR test		Total positive
Groups	Ag+	Ag-	PCR+	PCR-	Total positive
I. clinical signs (n = 21)	21	0	21	0	21 (100%)
II. close contact with parvovirus-infected animals (n = 29)	2	27	2	27	2 (6.89%)
III. clinically healthy (n = 9)	0	9	0	9	0

1 Ag+ – parvovirus infection clinically confirmed by commercial antigen test for canine parvovirus (CPV) and canine coronavirus Ag- – parvovirus infection clinically excluded by commercial antigen test; PCR+ – parvovirus infection confirmed by PCR PCR- – parvovirus infection excluded by PCR

Amplicons of the full-length *VP2* gene of canine parvovirus 2 (CPV-2) (1,755 bp) resolved on agarose gel as confirmation of parvovirus infection in European shorthair and crossbred cats in central Slovakia based on the presence of this gene in rectal swab samples. L – GeneRuler 1 kb DNA Ladder; I – group with clinical signs of parvovirus infection; II – group with close contact with parvovirus-infected animals; + – positive control (CPV-2-positive sample)

Table 4.

Sequences producing significant alignments with the VP2 gene amplicons of investigated rectal swab samples from European shorthair and crossbred cats in central Slovakia. Sequence analysis used the National Center for Biotechnology Information BLASTn algorithm

Scientific name	Pairwise identity (%)	Query coverage (%)	GenBank accession number
Feline panleukopenia virus	100.00	100	MK671185.1, MK671183.1, MK671171.1, MK671170.1, MK671156.1, MK425504.1, MK425500.1, MK425499.1, MK425498.1, MK425497.1, KP019621.2, MG764511.1, MG764510.1, MF541133.1, MF541132.1, MF541119.1, KX685354.1, KX900570.1, KT240130.1, KT357491.1, OP796716.1, OP796714.1, KP682520.1, KP019617.1, OM638042.1, MW091486.1, MW091487.1, MZ712026.1, MZ322607.1, MZ357122.1, MZ357120.1, MZ357119.1, MW017627.1, MT270583.1, MW331496.1, MN419003.1, MT274378.1, HQ184201.1, FJ936171.1, DQ474238.1, DQ474237.1, DQ474236.1, EU221281.1, AY606131.1, DQ099430.1, AY955826.1, DQ003301.1, AB054227.1, AB054226.1, AB054225.1
Feline parvovirus	100.00	100	MK266790.1, MK266788.1, MK295775.1, OM885375.1, ON646210.1, MZ442303.1, OR211675.1
Feline panleukopenia virus	99.78	100	OQ863619.1, OQ863618.1, OQ863617.1, OQ863615.1, MZ508524.1
Feline parvovirus	99.78	100	OR198066.1, OQ869254.1, OQ868569.1, OQ868568.1, OQ868566.1, OQ868565.1, OQ868564.1, OQ868562.1, OQ868554.1, OQ868553.1, OQ868552.1, OQ868550.1, OQ868548.1, OQ868547.1, OQ868542.1, OQ868536.1, OQ868535.1, OQ868534.1, OR194134.1, OR194132.1, OR194130.1, OR194129.1, OR194128.1, OR194125.1, OR194122.1, OQ535514.1, OQ535513.1, OQ535511.1, OQ535510.1, OQ535509.1

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/jvetres-2024-0021 | Journal eISSN: 2450-8608 (formerly 2300-3235)

Journal RSS Feed

Language: English

Page range: 199 - 205

Submitted on: Oct 20, 2023

Accepted on: Mar 28, 2024

Published on: Apr 15, 2024

Published by: National Veterinary Research Institute in Pulawy

In partnership with: Paradigm Publishing Services

Keywords:

parvovirus,

panleukopenia,

cats,

polymerase chain reaction,

VP2 gene

Related subjects:

Life sciences,

Molecular biology,

Microbiology and virology,

Life sciences, other,

Medicine,

Veterinary medicine

© 2024 Alexandra Citarová, Jana Mojžišová, Patrícia Petroušková, Andrea Pelegrinová, Maroš Kostičák, L’uboš Korytár, Marián Prokeš, Boris Vojtek, Anna Ondrejková, Monika Drážovská, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 68 (2024): Issue 2 (June 2024)

Investigation of canine parvovirus occurrence in cats with clinical signs of feline panleukopenia in Slovakia – pilot study

Figures & Tables

Table 1.

Table 2.

Table 3.

Fig. 1.

Table 4.

Paradigm

My account